Trial Profile

An Open, Single Arm,Multicenter Clinical Trial of Anlotinib Combined With Transcatheter Arterial Chemoembolization for Adjuvant Therapy in Patients With High Risk of Recurrence After Resection of Advanced Hepatocellular Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jan 2024 Results (data cut off March 2023) assessing efficacy and safety of anlotinib as maintenance adjuvant treatment following inductional TACE in patients with hepatocellular carcinoma were presented at the 2024 Gastrointestinal Cancers Symposium
06 Jun 2023 Updated results (at data cut off: January 15, 2023; n=29) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
12 Jan 2023 Planned End Date changed from 1 Jun 2022 to 1 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com